Company Profiles

driven by the PitchBook Platform

Symphogen

Symphogen
2000 FOUNDED
PRIVATE STATUS
91-100 EMPLOYEES
Conv. Debt LATEST DEAL TYPE
$75.8M LATEST DEAL AMOUNT
14 INVESTORS
Description

Developer of recombinant polyclonal antibodies designed to treat and prevent infectious diseases and cancer. The company's recombinant polyclonal antibodies include Sym001, a recombinant polyclonal antibody composition for the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns and Sym002, which includes recombinant polyclonal anti-vaccine virus antibodies to treat the adverse reactions caused by smallpox vaccinations, enabling cancer patients to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Pederstrupvej 93
  • 2750 Ballerup
  • Denmark

+45 45 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Symphogen’s full profile, request a free trial.

Symphogen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Convertible Debt 22-Oct-2015 $75.8M 00000 Completed Generating Revenue
8. Later Stage VC 03-May-2013 00000 00000 Completed Generating Revenue
7. Later Stage VC 04-Feb-2009 000.00 00000 Completed Generating Revenue
6. Later Stage VC 31-Jan-2007 00.00 000.00 Completed Generating Revenue
5. Later Stage VC (Series D) 08-Jan-2006 0000 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 02-Nov-2004 0000 000.00 Completed Startup
3. Early Stage VC (Series B) 000.00 Completed Startup
2. Early Stage VC (Series A) 23-Jan-2002 $15M $16.6M Completed Startup
1. Seed Round 01-Jan-2000 $1.64M $1.54M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Symphogen Investments & Acquisitions (2)

Company Name Date Type Deal Size Industry Lead Partner
000000 29-Jan-2015 000000000 00000 00 Biotechnology 0000000 000000 00.0
Receptor BioLogix 29-Jan-2009 Merger/Acquisition Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Symphogen Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Danica Pension Other Minority 000 0000 000000 0
Pensionskassernes Administration Limited Partner Minority 000 0000 000000 0
Genentech Corporation Minority 000 0000 000000 0
New Science Ventures Venture Capital Minority 000 0000 000000 0
Roche Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Symphogen Executive Team (14)

Name Title Board
Seat
Contact
Info
Martin Olin Chief Executive Officer
Jesper Bramming Chief Financial Officer
Gayle Mills Chief Business Officer
Ivan Horak MD Chief Scientific & Medical Officer and Head of Global Research & Development
Kirsten Drejer Ph.D Co-Founder, Executive Director and Board Member

1 Former Executive

You’re viewing 5 of 14 executives. Get the full list »

Symphogen Board Members (13)

Name Representing Role Since Contact
Info
Aleks Engel Ph.D Novo Holdings Board Member 000 0000
Annika Espander Self Board Member 000 0000
Annika Jansson Self Board Member 000 0000
Anthony Tolcher MD Self Board Member 000 0000
Arthur Franken Gilde Healthcare Partners Board Observer 000 0000
You’re viewing 5 of 13 board members. Get the full list »